Akiko Moriya‐Saito
National Hospital Organization(JP)Nagoya Medical Center(JP)
Publications by Year
Research Areas
Acute Lymphoblastic Leukemia research, Childhood Cancer Survivors' Quality of Life, Acute Myeloid Leukemia Research, Hematopoietic Stem Cell Transplantation, Chronic Myeloid Leukemia Treatments
Most-Cited Works
- → Prognostic factors of Erdheim–Chester disease: a nationwide survey in Japan(2018)34 cited
- → Risk-adjusted therapy for pediatric non-T cell ALL improves outcomes for standard risk patients: results of JACLS ALL-02(2020)33 cited
- → An overall characterization of pediatric acute lymphoblastic leukemia with CRLF2 overexpression(2014)29 cited
- → Outcome of TCF3‐PBX1 positive pediatric acute lymphoblastic leukemia patients in J apan: a collaborative study of Japan Association of Childhood Leukemia Study (JACLS) and Children's Cancer and Leukemia Study Group (CCLSG)(2014)29 cited
- → Spectrum of clinical and genetic features of patients with inherited platelet disorder with suspected predisposition to hematological malignancies: a nationwide survey in Japan(2016)26 cited
- → Discontinuation of l-asparaginase and poor response to prednisolone are associated with poor outcome of ETV6-RUNX1-positive pediatric B-cell precursor acute lymphoblastic leukemia(2019)23 cited
- → Low Incidence of Osteonecrosis in Childhood Acute Lymphoblastic Leukemia Treated With ALL-97 and ALL-02 Study of Japan Association of Childhood Leukemia Study Group(2018)22 cited
- → Negative CD19 expression is associated with inferior relapse‐free survival in children with RUNX1‐RUNX1T1–positive acute myeloid leukaemia: results from the Japanese Paediatric Leukaemia/Lymphoma Study Group AML‐05 study(2019)15 cited
- → The incidence of symptomatic osteonecrosis is similar between Japanese children and children in Western countries with acute lymphoblastic leukaemia treated with a Berlin‐Frankfurt‐Münster (BFM)95‐based protocol(2021)7 cited
- → JACLS ALL-02 SR protocol reduced-intensity chemotherapy produces excellent outcomes in patients with low-risk childhood acute lymphoblastic leukemia(2022)7 cited